Ewing肉瘤的真实世界数据来自资源有限的环境,对治疗的依从性差,导致预后差。

IF 1.2 Q4 ONCOLOGY
ecancermedicalscience Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI:10.3332/ecancer.2024.1801
Nidhi Gupta, Kislay Dimri, Sudhir Kumar Garg, Aanchal Arora, Awadhesh Kumar Pandey
{"title":"Ewing肉瘤的真实世界数据来自资源有限的环境,对治疗的依从性差,导致预后差。","authors":"Nidhi Gupta, Kislay Dimri, Sudhir Kumar Garg, Aanchal Arora, Awadhesh Kumar Pandey","doi":"10.3332/ecancer.2024.1801","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is limited data from India on Ewing sarcoma (ES) patients. We analysed the demographic and clinical profile of ES patients, the systemic chemotherapy, local treatment and outcomes in patients with localised, metastatic and recurrent disease.</p><p><strong>Methods: </strong>Data of ES patients reporting from 2010 to 2019 to a tertiary care referral centre in north India was evaluated. A total of 81 patients were retrieved of whom 76 were assessed for treatment and outcomes. Patients were stratified as per localised (LD) or metastatic disease (MD). Outcomes were evaluated in terms of 3-year and 5-year disease-free survival (DFS) and overall survival (OS). Prognostic factors influencing OS for patients with LD were assessed.</p><p><strong>Results: </strong>The majority (68%, n = 55) of patients presented from rural areas with 30% (n = 24) presenting 6 months after the onset of symptoms, 63% (<i>n</i> = 51) had primary tumours more than 8 cm and 7% (<i>n</i> = 6) had a pathological fracture at presentation, 78% (<i>n</i> = 63) patients had LD while 22% (<i>n</i> = 18) patients had MD. Local treatment consisted of surgery in 56% (<i>n</i> = 28) patients and definitive radiotherapy in 44% (<i>n</i> = 22) patients. Compliance with chemotherapy was poor with patients receiving a median of five and seven cycles of chemotherapy as neoadjuvant and consolidation chemotherapy, respectively. Three-year OS for LD, MD and overall cohort was 41%, 6% and 32%, respectively. Size of the primary tumour > 8 cm, completion of less than 15 cycles of chemotherapy and presence of MD was associated with inferior survival on multivariate analysis.</p><p><strong>Conclusion: </strong>Poor outcomes were reported in this cohort of ES patients from a resource-limited setting where patients have a delayed diagnosis, advanced disease and poor compliance to adjuvant consolidation chemotherapy secondary to geographical, social and financial barriers. There is an urgent need to address these barriers for low middle-income countries to improve outcomes.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1801"},"PeriodicalIF":1.2000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735143/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real world data of Ewing sarcoma from a resource-limited setting with poor compliance to treatment leading to poor outcomes.\",\"authors\":\"Nidhi Gupta, Kislay Dimri, Sudhir Kumar Garg, Aanchal Arora, Awadhesh Kumar Pandey\",\"doi\":\"10.3332/ecancer.2024.1801\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is limited data from India on Ewing sarcoma (ES) patients. We analysed the demographic and clinical profile of ES patients, the systemic chemotherapy, local treatment and outcomes in patients with localised, metastatic and recurrent disease.</p><p><strong>Methods: </strong>Data of ES patients reporting from 2010 to 2019 to a tertiary care referral centre in north India was evaluated. A total of 81 patients were retrieved of whom 76 were assessed for treatment and outcomes. Patients were stratified as per localised (LD) or metastatic disease (MD). Outcomes were evaluated in terms of 3-year and 5-year disease-free survival (DFS) and overall survival (OS). Prognostic factors influencing OS for patients with LD were assessed.</p><p><strong>Results: </strong>The majority (68%, n = 55) of patients presented from rural areas with 30% (n = 24) presenting 6 months after the onset of symptoms, 63% (<i>n</i> = 51) had primary tumours more than 8 cm and 7% (<i>n</i> = 6) had a pathological fracture at presentation, 78% (<i>n</i> = 63) patients had LD while 22% (<i>n</i> = 18) patients had MD. Local treatment consisted of surgery in 56% (<i>n</i> = 28) patients and definitive radiotherapy in 44% (<i>n</i> = 22) patients. Compliance with chemotherapy was poor with patients receiving a median of five and seven cycles of chemotherapy as neoadjuvant and consolidation chemotherapy, respectively. Three-year OS for LD, MD and overall cohort was 41%, 6% and 32%, respectively. Size of the primary tumour > 8 cm, completion of less than 15 cycles of chemotherapy and presence of MD was associated with inferior survival on multivariate analysis.</p><p><strong>Conclusion: </strong>Poor outcomes were reported in this cohort of ES patients from a resource-limited setting where patients have a delayed diagnosis, advanced disease and poor compliance to adjuvant consolidation chemotherapy secondary to geographical, social and financial barriers. There is an urgent need to address these barriers for low middle-income countries to improve outcomes.</p>\",\"PeriodicalId\":11460,\"journal\":{\"name\":\"ecancermedicalscience\",\"volume\":\"18 \",\"pages\":\"1801\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735143/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ecancermedicalscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3332/ecancer.2024.1801\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2024.1801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:印度关于尤文氏肉瘤(ES)患者的数据有限。我们分析了ES患者的人口统计学和临床概况、全身化疗、局部治疗以及局部、转移性和复发性疾病患者的预后。方法:对2010年至2019年在印度北部三级医疗转诊中心报告的ES患者的数据进行评估。共纳入81例患者,其中76例接受治疗和预后评估。根据局部(LD)或转移性疾病(MD)对患者进行分层。结果根据3年和5年无病生存(DFS)和总生存(OS)进行评估。评估影响LD患者OS的预后因素。结果:多数病人(68%,n = 55)提出了从农村有30% (n = 24) 6个月后出现症状,63% (n = 51)初级肿瘤超过8厘米和7% (n = 6)在演讲中,病理骨折78% (n = 63)患者LD而22% (n = 18)患者。当地的治疗包括手术在56% (n = 28)患者和明确的44% (n = 22)患者的放射治疗。化疗依从性较差,患者分别接受中位5和7个化疗周期作为新辅助化疗和巩固化疗。LD、MD和总体队列的3年生存率分别为41%、6%和32%。多因素分析显示,原发肿瘤的大小约为8cm,化疗周期少于15个周期,以及MD的存在与较差的生存率相关。结论:在这个资源有限的ES患者队列中,由于地理、社会和经济障碍,患者诊断延迟,疾病晚期,对辅助巩固化疗的依从性较差,结果较差。迫切需要消除这些障碍,以帮助中低收入国家改善成果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real world data of Ewing sarcoma from a resource-limited setting with poor compliance to treatment leading to poor outcomes.

Background: There is limited data from India on Ewing sarcoma (ES) patients. We analysed the demographic and clinical profile of ES patients, the systemic chemotherapy, local treatment and outcomes in patients with localised, metastatic and recurrent disease.

Methods: Data of ES patients reporting from 2010 to 2019 to a tertiary care referral centre in north India was evaluated. A total of 81 patients were retrieved of whom 76 were assessed for treatment and outcomes. Patients were stratified as per localised (LD) or metastatic disease (MD). Outcomes were evaluated in terms of 3-year and 5-year disease-free survival (DFS) and overall survival (OS). Prognostic factors influencing OS for patients with LD were assessed.

Results: The majority (68%, n = 55) of patients presented from rural areas with 30% (n = 24) presenting 6 months after the onset of symptoms, 63% (n = 51) had primary tumours more than 8 cm and 7% (n = 6) had a pathological fracture at presentation, 78% (n = 63) patients had LD while 22% (n = 18) patients had MD. Local treatment consisted of surgery in 56% (n = 28) patients and definitive radiotherapy in 44% (n = 22) patients. Compliance with chemotherapy was poor with patients receiving a median of five and seven cycles of chemotherapy as neoadjuvant and consolidation chemotherapy, respectively. Three-year OS for LD, MD and overall cohort was 41%, 6% and 32%, respectively. Size of the primary tumour > 8 cm, completion of less than 15 cycles of chemotherapy and presence of MD was associated with inferior survival on multivariate analysis.

Conclusion: Poor outcomes were reported in this cohort of ES patients from a resource-limited setting where patients have a delayed diagnosis, advanced disease and poor compliance to adjuvant consolidation chemotherapy secondary to geographical, social and financial barriers. There is an urgent need to address these barriers for low middle-income countries to improve outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
5.60%
发文量
138
审稿时长
27 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信